Compare TJX Companies Inc (TJX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TJX Companies Inc vs Twist Bioscience Corp — how do they compare? TJX Companies Inc trades at $153.59 (market cap $172.05B), while Twist Bioscience Corp trades at $123.76 (market cap $7.72B). The key difference: TJX Companies Inc is far larger — about 22.3× Twist Bioscience Corp's market cap, and TJX Companies Inc pays a 1.23% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TJX | TWST | |
|---|---|---|
Market Cap | $172.05B | $7.72B |
Sector | Consumer Cyclical | Health |
52-Week High | $168.41 | $124.88 |
52-Week Low | $132.62 | $24.16 |
Enterprise Value | $180.65B | $7.65B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TJX trades at $154.17, down 2.92% over the past day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.19 exceeding the $1.02 estimate. Revenue grew to $56.36 billion in 2025, and net income margin improved to 8.63%. Analysts maintain a bullish consensus with an average price target of $181.80, citing momentum and value prospects.
The outlook for TJX remains positive driven by consistent earnings outperformance and robust profitability metrics like a 61.25% ROE. Key risks include competitive pressures in discount retail and sensitivity to consumer spending trends. The stock offers upside to analyst targets but faces near-term technical headwinds.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
